R&D Trends

Eli Lilly, Sanford-Burnham collaborate to investigate immunological therapies

Friday, May 15, 2015 02:15 PM

Eli Lilly and Sanford-Burnham Medical Research Institute, a nonprofit medical research institute based in Florida, are collaborating to discover and develop immunological therapies. The company will investigate potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders.

More... »


The Center for Drug R&D, IRICoR partner

Thursday, May 14, 2015 01:20 PM

The Institute for Research in Immunology and Cancer—Commercialization of Research (IRICoR) at the Université de Montréal (UdeM) and the Center for Drug R&D (CDRD) have initiated collaborations on three new drug development projects. These projects, which address areas of high unmet medical need, are being supported by funding from Merck & Co. to IRICoR.

More... »


Sanofi, Selecta Biosciences extend partnership on synthetic vaccine particle technology

Thursday, May 14, 2015 01:18 PM

Sanofi, in relation to an existing collaboration, has exercised its option to an exclusive license to develop an immunotherapy for the treatment of celiac disease with Selecta Biosciences, a Watertown, Mass.-based clinical stage biotechnology company developing a novel class of targeted antigen-specific immune therapies.

More... »

WHO draws lessons from Ebola to prepare roadmap for future epidemics

Wednesday, May 13, 2015 12:17 PM

The World Health Organization (WHO) has concluded a meeting on Ebola R&D to look at lessons learned from the outbreak and develop a roadmap for future epidemics.

More... »

AstraZeneca inks personalized medicine partnerships with Abbott, Montreal Heart Institute

Wednesday, May 13, 2015 12:07 PM

AstraZeneca has formed collaborations with the Montreal Heart Institute (MHI) in Quebec, Canada, to search the genomes of up to 80,000 patients for genes associated with cardiovascular diseases and diabetes, their complications and treatment outcomes, and with Abbott to develop companion diagnostic tests to identify patients with severe asthma who are most likely to benefit from the investigational biological therapy tralokinumab.

More... »

Eli Lilly, BioNTech form immune system research collaboration

Wednesday, May 13, 2015 11:56 AM

Eli Lilly and Biopharmaceutical New Technologies (BioNTech), a Germany-based immunotherapy company, have entered into a research collaboration to discover novel cancer immunotherapies. The companies will seek to use the power of the body’s own immune system to attack cancer cells and create possible new treatment options for cancer patients.

More... »

The Michael J. Fox Foundation, Imago Pharmaceuticals partner

Monday, May 11, 2015 03:15 PM

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has acquired a library of research tools around the parkin protein from Imago Pharmaceuticals. The Foundation believes these tools—cell lines, plasmids, compounds and more—will accelerate biological study and drug development against this promising disease-modification target.

More... »

UNC-Chapel Hill, GSK partner for HIV cure, launch Qura Therapeutics

Monday, May 11, 2015 02:06 PM

The University of North Carolina at Chapel Hill, a global public research university with experience in HIV basic and clinical research, and GlaxoSmithKline have created the dedicated HIV Cure Center and a jointly owned new company that will focus on discovering a cure for HIV/AIDS. This unique public-private partnership will redefine the traditional way of conducting research and create a new model to seek the breakthroughs needed to tackle a global health issue.

More... »

Juno Therapeutics, Fate Therapeutics collaborate on T cell immunotherapies

Thursday, May 7, 2015 12:19 PM

Juno Therapeutics, based in Seattle, and Fate Therapeutics, headquartered in San Diego, have executed a four-year strategic research collaboration and license agreement to identify and utilize small molecules to modulate Juno's genetically-engineered T cell product candidates to improve their therapeutic potential for cancer patients.

More... »

Report: Total global spending on oncology medicines reached $100B in 2014

Wednesday, May 6, 2015 02:53 PM

Earlier diagnosis, longer treatment duration and increased effectiveness of drug therapies are contributing to rising levels of spending on medicines for cancer care, according to a new report released by the IMS Institute for Healthcare Informatics, a global information and technology services company based in Parsippany, N.J. The report stated total global spending on oncology medicines—including therapeutic treatments and supportive care—reached the $100 billion threshold in 2014, even as the share of total medicine spending of oncologics increased only modestly.

More... »

CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs